Table 3

Costs (2011 US$) and utilities input in the model
Parameter Base-case (range) Source/comment
Antiviral drug costs
Lamivudine (100 mg) 2.07(1.86-2.27) Local charge
Adefovir (10 mg) 2.31 (2.15-3.08) Local charge
Entecavir (1000 mg) 10.20 (8–10.2) Local charge
Tenofovir (300 mg) 6.00 (4.62-7.69) The price and range were assumed
Annual health state costs
Lamivudine-resistant CHB 138.7(104.62-209.23) Assumed similar to naïve CHB [5]
Multi-resistant CHB 138.7(104.62-209.23) Assumed similar to lamivudine-resistant CHB [5]
Virological response 138.7(104.62-209.23)      [5]
Compensated cirrhosis 235.37(209.23-313.85)      [5]
Decompensated cirrhosis 2122.55(1569.23-2615.38)      [5]
HCC 5914.78(5230.77-10461.54)      [5]
Liver transplantation 46152.94(44984.62-52307.69)      [5]
Post-liver-transplantation 7691.63(7323.08-9415.38)      [5]
Utilities (quality of life)
Lamivudine-resistant CHB 0.52(0.5-0.7)      [34]
Multi-resistant CHB 0.52(0.5-0.7)      [34]
Virological response 0.71(0.65-0.8)      [34]
Compensated cirrhosis 0.57(0.5-0.7)      [34]
Decompensated cirrhosis 0.26(0.2-0.35)      [34]
HCC 0.31(0.24-0.38)      [34]
Liver transplantation 0.7(0.54-0.76)      [34]

CHB, chronic hepatitis B.

Wu et al.

Wu et al. BMC Health Services Research 2012 12:385   doi:10.1186/1472-6963-12-385

Open Data